Cargando…

Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom

BACKGROUND: Evaluating large-scale disease management interventions implemented in actual health care settings is a complex undertaking for which universally accepted methods do not exist. Fundamental issues, such as a lack of control patients and limited generalizability, hamper the use of the ‘gol...

Descripción completa

Detalles Bibliográficos
Autores principales: Elissen, Arianne MJ, Adams, John L, Spreeuwenberg, Marieke, Duimel-Peeters, Inge GP, Spreeuwenberg, Cor, Linden, Ariel, Vrijhoef, Hubertus JM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626873/
https://www.ncbi.nlm.nih.gov/pubmed/23497125
http://dx.doi.org/10.1186/1471-2288-13-40
_version_ 1782266261075394560
author Elissen, Arianne MJ
Adams, John L
Spreeuwenberg, Marieke
Duimel-Peeters, Inge GP
Spreeuwenberg, Cor
Linden, Ariel
Vrijhoef, Hubertus JM
author_facet Elissen, Arianne MJ
Adams, John L
Spreeuwenberg, Marieke
Duimel-Peeters, Inge GP
Spreeuwenberg, Cor
Linden, Ariel
Vrijhoef, Hubertus JM
author_sort Elissen, Arianne MJ
collection PubMed
description BACKGROUND: Evaluating large-scale disease management interventions implemented in actual health care settings is a complex undertaking for which universally accepted methods do not exist. Fundamental issues, such as a lack of control patients and limited generalizability, hamper the use of the ‘gold-standard’ randomized controlled trial, while methodological shortcomings restrict the value of observational designs. Advancing methods for disease management evaluation in practice is pivotal to learn more about the impact of population-wide approaches. Methods must account for the presence of heterogeneity in effects, which necessitates a more granular assessment of outcomes. METHODS: This paper introduces multilevel regression methods as valuable techniques to evaluate ‘real-world’ disease management approaches in a manner that produces meaningful findings for everyday practice. In a worked example, these methods are applied to retrospectively gathered routine health care data covering a cohort of 105,056 diabetes patients who receive disease management for type 2 diabetes mellitus in the Netherlands. Multivariable, multilevel regression models are fitted to identify trends in clinical outcomes and correct for differences in characteristics of patients (age, disease duration, health status, diabetes complications, smoking status) and the intervention (measurement frequency and range, length of follow-up). RESULTS: After a median one year follow-up, the Dutch disease management approach was associated with small average improvements in systolic blood pressure and low-density lipoprotein, while a slight deterioration occurred in glycated hemoglobin. Differential findings suggest that patients with poorly controlled diabetes tend to benefit most from disease management in terms of improved clinical measures. Additionally, a greater measurement frequency was associated with better outcomes, while longer length of follow-up was accompanied by less positive results. CONCLUSIONS: Despite concerted efforts to adjust for potential sources of confounding and bias, there ultimately are limits to the validity and reliability of findings from uncontrolled research based on routine intervention data. While our findings are supported by previous randomized research in other settings, the trends in outcome measures presented here may have alternative explanations. Further practice-based research, perhaps using historical data to retrospectively construct a control group, is necessary to confirm results and learn more about the impact of population-wide disease management.
format Online
Article
Text
id pubmed-3626873
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36268732013-04-16 Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom Elissen, Arianne MJ Adams, John L Spreeuwenberg, Marieke Duimel-Peeters, Inge GP Spreeuwenberg, Cor Linden, Ariel Vrijhoef, Hubertus JM BMC Med Res Methodol Research Article BACKGROUND: Evaluating large-scale disease management interventions implemented in actual health care settings is a complex undertaking for which universally accepted methods do not exist. Fundamental issues, such as a lack of control patients and limited generalizability, hamper the use of the ‘gold-standard’ randomized controlled trial, while methodological shortcomings restrict the value of observational designs. Advancing methods for disease management evaluation in practice is pivotal to learn more about the impact of population-wide approaches. Methods must account for the presence of heterogeneity in effects, which necessitates a more granular assessment of outcomes. METHODS: This paper introduces multilevel regression methods as valuable techniques to evaluate ‘real-world’ disease management approaches in a manner that produces meaningful findings for everyday practice. In a worked example, these methods are applied to retrospectively gathered routine health care data covering a cohort of 105,056 diabetes patients who receive disease management for type 2 diabetes mellitus in the Netherlands. Multivariable, multilevel regression models are fitted to identify trends in clinical outcomes and correct for differences in characteristics of patients (age, disease duration, health status, diabetes complications, smoking status) and the intervention (measurement frequency and range, length of follow-up). RESULTS: After a median one year follow-up, the Dutch disease management approach was associated with small average improvements in systolic blood pressure and low-density lipoprotein, while a slight deterioration occurred in glycated hemoglobin. Differential findings suggest that patients with poorly controlled diabetes tend to benefit most from disease management in terms of improved clinical measures. Additionally, a greater measurement frequency was associated with better outcomes, while longer length of follow-up was accompanied by less positive results. CONCLUSIONS: Despite concerted efforts to adjust for potential sources of confounding and bias, there ultimately are limits to the validity and reliability of findings from uncontrolled research based on routine intervention data. While our findings are supported by previous randomized research in other settings, the trends in outcome measures presented here may have alternative explanations. Further practice-based research, perhaps using historical data to retrospectively construct a control group, is necessary to confirm results and learn more about the impact of population-wide disease management. BioMed Central 2013-03-14 /pmc/articles/PMC3626873/ /pubmed/23497125 http://dx.doi.org/10.1186/1471-2288-13-40 Text en Copyright © 2013 Elissen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Elissen, Arianne MJ
Adams, John L
Spreeuwenberg, Marieke
Duimel-Peeters, Inge GP
Spreeuwenberg, Cor
Linden, Ariel
Vrijhoef, Hubertus JM
Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom
title Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom
title_full Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom
title_fullStr Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom
title_full_unstemmed Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom
title_short Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom
title_sort advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626873/
https://www.ncbi.nlm.nih.gov/pubmed/23497125
http://dx.doi.org/10.1186/1471-2288-13-40
work_keys_str_mv AT elissenariannemj advancingcurrentapproachestodiseasemanagementevaluationcapitalizingonheterogeneitytounderstandwhatworksandforwhom
AT adamsjohnl advancingcurrentapproachestodiseasemanagementevaluationcapitalizingonheterogeneitytounderstandwhatworksandforwhom
AT spreeuwenbergmarieke advancingcurrentapproachestodiseasemanagementevaluationcapitalizingonheterogeneitytounderstandwhatworksandforwhom
AT duimelpeetersingegp advancingcurrentapproachestodiseasemanagementevaluationcapitalizingonheterogeneitytounderstandwhatworksandforwhom
AT spreeuwenbergcor advancingcurrentapproachestodiseasemanagementevaluationcapitalizingonheterogeneitytounderstandwhatworksandforwhom
AT lindenariel advancingcurrentapproachestodiseasemanagementevaluationcapitalizingonheterogeneitytounderstandwhatworksandforwhom
AT vrijhoefhubertusjm advancingcurrentapproachestodiseasemanagementevaluationcapitalizingonheterogeneitytounderstandwhatworksandforwhom